Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Comprehensive (Loss) Income	Accumulated Deficit	Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2023	$ 44	$ 497,506	$ (48)	$ (261,182)	$ 236,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2023	44,038,333
Exercises of vested stock options		78			78
Exercises of vested stock options (in shares)	32,500
Vesting of restricted stock units (in shares)	324,520
Issuance of common stock	$ 2	19,303			19,305
Issuance of common stock (in shares)	2,145,002
Issuance of common stock and pre-funded warrants in connection with underwritten public offering	$ 8	93,465			93,473
Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares )	7,777,778
Stock-based compensation expense		3,498			3,498
Unrealized gain (loss) on available-for-sale securities, net of tax			(458)		(458)
Net loss				(11,330)	(11,330)
Stockholders' Equity, Ending Balance at Mar. 31, 2024	$ 54	613,850	(506)	(272,512)	340,886
Shares, Outstanding, Ending Balance at Mar. 31, 2024	54,318,133
Stockholders' Equity, Beginning Balance at Dec. 31, 2024	$ 55	626,296	(407)	(326,184)	299,760
Shares, Outstanding, Beginning Balance at Dec. 31, 2024	54,731,316
Exercises of vested stock options		82			$ 82
Exercises of vested stock options (in shares)	27,613				27,613
Vesting of restricted stock units (in shares)	450,556
Stock-based compensation expense		3,673			$ 3,673
Unrealized gain (loss) on available-for-sale securities, net of tax			208		208
Net loss				(31,021)	(31,021)
Stockholders' Equity, Ending Balance at Mar. 31, 2025	$ 55	$ 630,051	$ (199)	$ (357,205)	$ 272,702
Shares, Outstanding, Ending Balance at Mar. 31, 2025	55,209,485